Pay in 4 interest-free payments of $6.60 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
No active ingredients targeting the follicle
hospitalization required Maintenance of Remission: Immunomodulators (azathioprine, 6-MP, methotrexate) for steroid-dependent or frequently-relapsing disease Biologic monotherapy or combination therapy (biologic + immunomodulator) for moderate-to-severe disease Step-up or top-down approach based on disease severity, patient risk factors, and prior therapy Biologic Therapy Targets: TNF-: Infliximab (IV), adalimumab (SC), certolizumab pegol (SC) IL-12/23: Ustekinumab (IV induction, SC maintenance) Integrin: Vedolizumab (IV) IL-23: Risankizumab (IV induction, SC maintenance) JAK inhibition: Upadacitinib (oral) Surgical Management Surgery is indicated in approximately 7080% of patients with Crohns disease over their lifetime, per StatPearls
Vomero M, Finucci A, Barbati C, Colasanti T, Ceccarelli F, Novelli L, et al
NAD plus, and the mitochondrial side of recovery NAD+ is a different molecule for a different problem
US$ 28.29
US$ 24.37
US$ 24.88
